EUVIMEDEUVIMED entdecken
Crossref

Structure‐Based Prediction of QT Prolongation Risk Using Graph Neural Networks: An Integrative Approach Combining In Vitro hERG Assays and Pharmacovigilance Data

Tomoyuki Enokiya iD, Ryosuke Kunitomo, Takamasa Yamaguchi

Clinical Pharmacology & Therapeutics · 2026-06 · 119 (6) · 1662-1670

DOI: 10.1002/cpt.70220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 06.02.2026. Verfasst von Tomoyuki Enokiya und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacoinformatics, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, S…. Hauptthemen laut MEDLINE: Pharmacovigilance, Long QT Syndrome, ERG1 Potassium Channel. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug‐induced QT‐interval prolongation, a non‐specific biomarker of increased risk for Torsades de Pointes (TdP), is a major safety concern in drug development. While in vitro hERG inhibition assays are required for early‐phase screening, pharmacovigilance data from sources like the FDA Adverse Event Reporting System (FAERS) provide complementary insights. Integrating these heterogeneous data with molecular structure offers a promising, yet underutilized approach to predict proarrhythmic risk. We developed an interpretable graph neural network (GNN) framework integrating in vitro hERG inhibition data (PubChem AID 588834), FAERS‐derived pharmacovigilance signals, and molecular structure information. Canonical SMILES were converted into molecular graphs using RDKit, and atom‐ and bond‐level features were encoded. Four GNN architectures (GINE, GCN, GraphSAGE, and GATv2) were compared via stratified five‐fold cross‐validation. The best‐performing model, GATv2, was further interpreted using Integrated Gradients to identify structural features contributing to QT liability. The final data set comprised 4,808 small molecules with binary QT‐risk labels. GATv2 achieved a cross‐validated ROC‐AUC of 0.838, PR‐AUC of 0.830, and F1‐score of 0.756. Retraining on the full data set yielded ROC‐AUC 0.918, PR‐AUC 0.908, and F1‐score 0.847. External validation on an independent hERG assay (AID 1671200, n = 2,405) confirmed strong performance (ROC‐AUC 0.859, sensitivity 0.80, specificity 0.82). Atomic degree and hydrogen count were dominant predictors, consistent with known SARs. This GNN‐based framework integrates structural and pharmacological data to predict QT risk, providing a transparent, structure‐based decision‐support tool aligned with ICH S7B/E14 and CiPA guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceLong QT SyndromeERG1 Potassium ChannelHumansGraph Neural NetworksAdverse Drug Reaction Reporting SystemsRisk AssessmentTorsades de PointesDrug-Related Side Effects and Adverse Reactions

Substanzen

ERG1 Potassium Channel

Autor:innen und Institutionen

  • Laboratory of Pharmacoinformatics, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.
  • Laboratory of Pharmacoinformatics, Division of Clinical Pharmacy and Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.

ORCID-Profile: Tomoyuki Enokiya

Zitieren

APA

Enokiya, T., Kunitomo, R., & Yamaguchi, T. (2026). Structure‐Based Prediction of QT Prolongation Risk Using Graph Neural Networks: An Integrative Approach Combining In Vitro hERG Assays and Pharmacovigilance Data. Clinical Pharmacology & Therapeutics, 119(6), 1662-1670. https://doi.org/10.1002/cpt.70220

Vancouver

Enokiya T, Kunitomo R, Yamaguchi T. Structure‐Based Prediction of QT Prolongation Risk Using Graph Neural Networks: An Integrative Approach Combining In Vitro hERG Assays and Pharmacovigilance Data. Clinical Pharmacology & Therapeutics. 2026;119(6):1662-1670. doi:10.1002/cpt.70220

BibTeX
@article{Enokiya2026,
  author = {Enokiya, Tomoyuki and Kunitomo, Ryosuke and Yamaguchi, Takamasa},
  title = {Structure‐Based Prediction of QT Prolongation Risk Using Graph Neural Networks: An Integrative Approach Combining In Vitro hERG Assays and Pharmacovigilance Data},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {6},
  pages = {1662--1670},
  doi = {10.1002/cpt.70220}
}
Kostenlos starten →